| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2850575 | American Heart Journal | 2009 | 12 Pages |
Abstract
TRA
- CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies.
- CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
The TRAâ¢CER Executive and Steering Committees The TRAâ¢CER Executive and Steering Committees,